LeonaBio, Inc. - Asset Resilience Ratio
LeonaBio, Inc. (LONA) has an Asset Resilience Ratio of 20.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of LeonaBio, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how LeonaBio, Inc.'s Asset Resilience Ratio has changed over time. See LeonaBio, Inc. (LONA) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down LeonaBio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LONA market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.05 Million | 20.68% |
| Total Liquid Assets | $19.05 Million | 20.68% |
Asset Resilience Insights
- Good Liquidity Position: LeonaBio, Inc. maintains a healthy 20.68% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
LeonaBio, Inc. Industry Peers by Asset Resilience Ratio
Compare LeonaBio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for LeonaBio, Inc. (2018–2025)
The table below shows the annual Asset Resilience Ratio data for LeonaBio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.68% | $19.05 Million | $92.15 Million | +15.85pp |
| 2024-12-31 | 4.83% | $2.84 Million | $58.78 Million | -30.64pp |
| 2023-12-31 | 35.47% | $56.84 Million | $160.25 Million | -4.97pp |
| 2022-12-31 | 40.43% | $104.38 Million | $258.15 Million | -2.71pp |
| 2021-12-31 | 43.14% | $143.22 Million | $332.01 Million | -1.24pp |
| 2020-12-31 | 44.38% | $124.06 Million | $279.56 Million | +13.97pp |
| 2018-12-31 | 30.41% | $1.50 Million | $4.93 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds whic… Read more